Inex Countersues Protiva, Returning Fire in Battle Over Rights to Delivery Technology | GenomeWeb

Inex Pharmaceuticals last week fired back against one-time subsidiary Protiva Biotherapeutics in a legal dispute over the rights to an drug-delivery technology. In a countersuit filed in the Supreme Court of British Columbia Inex claims that Protiva had limited rights to the delivery technology and was obligated to license back to Inex any improvements made to it.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.